Abstract
The phenylpteridine derivative BIBW22BS (BIBW22) is a potent modulator of multidrug resistance (MDR). We investigated BIBW22 in comparison to dexniguldipine and verapamil as modifier of MDR in blasts of de novo, relapsed or persistent acute myeloid leukemia (AML) in vitro. All patients with relapsed or persistent AML had been pretreated with idarubicin and cytosine arabinoside. The degree of MDR was determined by efflux kinetics of rhodamine 123 (R123), daunorubicin, and idarubicin measured by flow cytometry (FACS). A total of 51 patients with AML, 25 de novo and 26 relapsed or persistent, were investigated. While only 6 out of 25 de novo AML blast populations showed moderate efflux of R123 and daunorubicin, 17 out of 26 blast populations of relapsed or persistent AML had an efflux between 20% and 44% within 15 min ex vivo. This efflux could be significantly inhibited by 1 microM BIBW22, 1 microM dexniguldipine, or 10 microM verapamil. For idarubicin we found an effusion of 40+/-9% within 15 min in all blast populations that could not be inhibited by the modulators. Clinically achievable drug concentrations causing only moderate side-effects are in the range of 0.5 microM dexniguldipine and 3 microM verapamil. Up to now, BIBW22...Continue Reading
References
Dec 4, 1992·Science·S P ColeR G Deeley
Oct 1, 1992·British Journal of Haematology·C SelleriB Rotoli
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R VoglerP L Banks
Feb 1, 1991·Current Opinion in Oncology·D D Ross
Sep 1, 1990·Cancer·Y KuwazuruS Akiyama
Dec 1, 1990·Cancer Treatment Reviews·S B Kaye
May 15, 1991·Journal of the National Cancer Institute·M R Baer, C D Bloomfield
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Jan 1, 1990·Leukemia Research·H SatoH D Preisler
Nov 15, 1989·Biochemical Pharmacology·B Schott, J Robert
Aug 3, 1988·Biochimica Et Biophysica Acta·G BradleyV Ling
Nov 1, 1986·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·J M MansonJ San Sebastian
Mar 1, 1985·Somatic Cell and Molecular Genetics·S AkiyamaM M Gottesman
Jan 1, 1994·Cytometry·M R MüllerS Seeber
Oct 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J JansenE Boven
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H L McLeod
Apr 1, 1994·Leukemia Research·K Nooter, P Sonneveld
Citations
Apr 28, 2000·Leukemia Research·J K SchröderJ Schütte
Jan 14, 1999·British Journal of Haematology·J K SchröderJ Schütte
Oct 6, 1997·Pathology International·T KakiharaI Emura
Sep 12, 1998·British Journal of Haematology·E WattelP Fenaux
Mar 23, 2011·Cancer·Celeste BelloJeffrey E Lancet
Nov 13, 2010·Journal of Cellular and Molecular Medicine·Dan-Dan FengYue-Qin Chen
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shuzhong Zhang, Marilyn E Morris
Nov 24, 2001·Blood·A F ListF R Appelbaum
Jul 2, 2002·Blood·Xing Q PanRobert J Lee
Jun 5, 2001·Blood·M Feuring-Buske, D E Hogge
May 23, 2001·Blood·M M van den Heuvel-EibrinkP Sonneveld
Dec 30, 1999·Cell Proliferation·J BoutonnatD Seigneurin